Introduction
The ability to track the expression of a newly introduced transgene in living organisms may enhance progress in gene therapy. In particular, one would want to image the biodistribution, magnitude, and duration of a therapeutic gene's expression once it is introduced in vivo. Confirming that the transgene is expressed primarily at its target site is particularly important when the therapeutic gene is a suicide gene, producing a cytotoxic protein. For example, many attempts have been made to deliver the suicide gene, herpes simplex virus type 1 thymidine kinase (HSV1-tk), to particular cancer cells. [1] [2] [3] [4] [5] [6] In gene augmentation therapy, where the purpose is to restore the magnitude of a normal gene's expression to appropriate levels, it is essential to track the therapeutic gene's expression level in the living subject. [7] [8] [9] [10] Measuring duration of expression of the therapeutic gene will also be of critical importance when using gene augmentation therapy in the clinic. Imaging the biodistribution of the that cells co-infected with equivalent titers of Ad-CMV-HSV1-sr39tk and Ad-CMV-D 2 R express both reporter genes with good correlation (r 2 = 0.93). Similarly, a high correlation (r 2 = 0.97) was observed between the expression of both PRGs in the livers of mice co-infected via tail-vein injection with equivalent titers of these two adenoviruses. Finally, microPET imaging of HSV1-sr39tk and D 2 R expression with 9-(4-[ therapeutic gene's expression can also be used to predict possible side-effects of gene therapy.
One possible approach to imaging gene expression in living animals, utilizes positron emission tomography (PET) reporter genes (PRG) and PET reporter probes (PRP). [11] [12] [13] [14] [15] [16] [17] Current validated PRG/PRP systems measure either enzyme products of a reporter gene, which phosphorylates a radio-labeled substrate and traps it intracellularly, or receptor protein products of a reporter gene that binds a radio-labeled ligand. [11] [12] [13] Examples of both types of PRG/PRP systems are the mutant HSV1-tk (HSV1-sr39tk) /9-(4-[ 16, [18] [19] [20] Through methods developed to establish a direct link between the expression of the therapeutic gene and the expression of a PRG, it should be possible to track biodistribution of a therapeutic gene's expression and quantitatively determine the level of its expression, by imaging the PRG.
Linking the expression of a therapeutic gene to a PRG can be done through a variety of different molecular constructs. One way is to clone both genes, side by side each other, downstream of a promoter, such that a single mRNA is transcribed from which a protein is translated that has the therapeutic and reporter proteins fused together. 21, 22 Another method is to construct a vector in which the therapeutic and the reporter genes are driven by a bidirectional promoter, transcripting separate mRNA from each gene which would then be translated into separate protein products. [23] [24] [25] Yet another approach is to position both genes on separate locations of the same vector, downstream of an identical, but independent, promoter. Therefore both genes are activated together and two separate mRNAs and proteins are produced. 26 A fourth novel approach is the incorporation of the therapeutic and the reporter gene in a bicistronic vector system in which a common promoter directs the transcription of a single mRNA, but an internal ribosomal entry site (IRES) separates the genes. [27] [28] [29] [30] In this approach a single mRNA will be produced from which the protein products of the therapeutic and reporter genes will each be separately translated.
Recently, we described a bicistronic vector system in which a common cytomegalovirus (CMV) promoter directs transcription of a single mRNA containing coding regions of two reporter genes separated by the encephalomyocarditis virus IRES. 28 The D 2 R reporter gene was placed upstream of IRES sequence and HSV1-sr39tk was placed downstream of the IRES (pCMV-D 2 R-IRES-HSV1-sr39tk). Cells stably transfected with pCMV-D 2 R-IRES-HSV1-sr39tk plasmid vector expressed both D 2 R and HSV1-sr39tk with high correlation. 27 using single photon emission computerized tomography (SPECT) reporter probes for the HSV1-tk reporter gene.
In the current study, we demonstrate that it is possible to macroscopically correlate the expression of two genes by regulating their transcription with the same promoter, but delivering them on separate adenoviral vectors. We make use of two adenoviruses, one carrying the HSV1-sr39tk PRG and another carrying the D 2 R PRG. We demonstrate highly correlated expression of D 2 R and HSV1-sr39tk in cultured cells co-infected with equal viral titers of Ad-CMV-HSV1-sr39tk and Ad-CMV-D 2 R and in the livers of mice co-injected intravenously with various equivalent titers of both adenoviruses. We confirm that it is possible to quantitatively image the expression of both PRGs with [ ]FESP retention correlates in those tissues. Therefore, our study provides initial evidence that it should be possible to image biodistribution, magnitude and duration of a therapeutic transgene's expression with a PRG, using this relatively simple approach.
Results
Linearly increasing levels of D 2 R and TK expression are observed in C6 glioma cells infected with increasing titers of Ad-CMV-D 2 R and Ad-CMV-HSV1-sr39tk In order to confirm that the levels of expression of the PRGs increase in accordance with the viral titer used to infect cells, we incubated C6 cells with increasing titers and b). The slope of the regression line in Figure 1a is 0.27 and in Figure 1b is Co-injection of equivalent titers of Ad-CMV-D 2 R and Ad-CMV-HSV1-sr39tk into the tail vein of mice leads to highly correlated expression of D 2 R and HSV1-sr39TK in their livers Eight Swiss Webster mice were co-injected various equivalent titers (0-1.5 × 10 9 p.f.u.) of Ad-CMV-D 2 R and Ad-CMV-HSV1-sr39tk into their tail veins (Ad5-dl434 was used to keep the total viral titer constant at 3.0 × 10 p.f.u.). Since adenoviruses administered intravenously primarily infect the liver, the livers of the dually adenovirus-infected mice were removed and assayed in vitro for TK enzyme activity and 31 1.0 × 10 9 p.f.u. of both Ad-CMV-D 2 R and Ad-CMV-HSV1-sr39tk were injected into the right hind leg (final concentration of both viruses was 1.0 × 10 7 p.f.u./l in a total volume of 100 l), and 0.5 × 10 9 p.f.u. of both Ad-CMV-D 2 R and Ad-CMV-HSV1-sr39tk was injected into the left hind leg (final concentration of Ad-CMV-D 2 R and Ad-CMV-HSV1-sr39tk was 0.5 × 10 7 p.f.u./l adjusted by adding 50 l of Ad5-dl434 to get a total volume of 100 l) of a nude mouse, 2 days before the start of imaging. Only Ad5-dl434 control was injected into the right paw of the nude mouse. The nude mouse shown in Figure 5 had one tumor xenograft over his neck (tumor 1) and one tumor xenograft over his buttocks (tumor 2). Tumor 1 was coinjected 1.0 × 10 9 p.f.u. of both Ad-CMV-D 2 R and Ad-CMV-HSV1-sr39tk on 3 consecutive days, before being imaged with [ Biodistribution and magnitude of D 2 R and HSV1-sr39TK expression is correlated at different time points To assess whether the expression of both PET reporter transgenes remains correlated in living mice over time, we co-injected equivalent titers of Ad-CMV-D 2 R and Ad-CMV-HSV1-sr39tk into the tail veins of both Swiss Webster mice (immunocompetent) and nude mice (immunodeficient). We followed expression of both PRGs, by [ Figure 6b is a demonstration of the same experiment in a nude mouse. The nude mouse was intravenously co-injected with 0.1 × 10 9 p.f.u. of Ad-CMV-D 2 R and Ad-CMV-HSV1-sr39tk and imaged at three different time-points extending to a month after the injection of the adenoviruses. The activity of both probes in the liver increased from the first to the second week after adenovirus injection and then remained relatively constant 2 weeks after that. 
Discussion
In this study we have demonstrated that the expression of the two reporter transgenes, HSV1-sr39tk and D 2 R, driven by the same constitutively active CMV promoter is well correlated at the multi-cell (macroscopic) and tissue level, even though both reporter genes are delivered utilizing separate adenoviral vectors. We observed good correlation between the activity of TK enzyme and D 2 R binding in two different cell types, that had been coinfected with varying but equivalent titers of Ad-CMV-HSV1-sr39tk and Ad-CMV-D 2 R, in cell culture. Furthermore, we observed excellent correlation between the penciclovir-phosphorylating activity of TK enzyme and spiperone binding of D 2 R in the livers of mice following coinjection of equivalent titers of Ad-CMV-HSV1-sr39tk and Ad-CMV-D 2 R. HSV1-sr39TK enzyme more effectively utilizes acycloguanosines such as ganciclovir ( 18 Our approach is likely to be applicable if wild-type HSV1-tk PRG is used, however at relatively low levels of HSV1-tk expression, there may be insufficient signal to detect over background levels.
The liver, muscle and tumor images in our study have shown that once Ad-CMV-D 2 R and Ad-CMV-HSV1-sr39tk are co-injected together, [ 
F]FHBG PET (section) images are averages of the planes that contain the tumors. The PET (section) images have been scaled to the injected dose. This mouse is representative of a larger data set.
Perhaps the greatest advantage of our approach is the convenience it will yield to animal or human therapeutic transgene pharmacokinetic experiments. This approach may eliminate the need for making a new construct every time an investigator needs to track the expression of the therapeutic gene in vivo. In fact many investigators have already delivered therapeutic genes regulated by the widely used CMV promoter. The idea behind this current approach is that host responses to a gene therapy vector will be the same whether it is carrying the therapeutic gene or if it is carrying a PRG. Therefore, either vector has an equal chance of uptake by the types of cells capable of infection by that specific type of vector. Furthermore, host responses that somehow eliminate the vector carrying the therapeutic gene will have an equal chance of eliminating the identical vector carrying the PRG. Therefore, one would speculate that a lack of correlation between the expression of a therapeutic gene and a PRG delivered by this approach would have to be due to genespecific regulation related to the nature of the expressed protein. Once validated in cell culture and in animal models that the PRG and the therapeutic gene which are driven by the same promoter are identically regulated, independent reporter gene vectors may be delivered simultaneously with the therapeutic gene vectors to track the biodistribution, duration and the level of expression of the therapeutic gene in living animals and in patients.
The fact that the identical promoters regulating the expression of the therapeutic gene and the PRG are on separate vectors may affect correlation between the genes. Cis-acting mechanisms of transcription regulation, due to positive and negative feedback from either the therapeutic gene or the PRG may reduce the correlation between their expression. This may not be a problem with the IRES, fusion protein and bidirectional promoter approaches for delivery of therapeutic and reporter genes, because any affect on the promoter will affect the transcription of both the therapeutic gene and the PET reporter gene. However, at the translational and posttranslational level all the approaches, except the fusion protein approach, may encounter loss of correlation between the protein products of the therapeutic gene and the PRG. In the bicistronic IRES construct, the expression of the gene downstream of the IRES sequence is attenuated, which might affect sensitivity of the reporter gene's detection or the efficacy of the therapeutic gene. Recently, IRES sequences were identified which may help to solve this problem. 32 In the fusion protein approach, the final quaternary folding of the fusion protein might affect the function of the therapeutic gene or influence the ability of the reporter probes to interact with reporter gene product. Whichever approach is used for imaging a new therapeutic gene, the correlation between expression of the therapeutic gene and PRG product should be examined in cell culture and animal models.
F]FHBG coronal images of (a) a Swiss Webster and (b) a nude mouse at three different time-points after co-injecting equivalent titers of Ad-CMV-HSV1-sr39tk and Ad-CMV-D
Another argument against delivering the therapeutic gene and the PRG on separate vectors is that not all cells may be equally infected with the PRG vector and the therapeutic gene vector. In contrast, in the other approaches both genes are constructed on the same vector; thus at the single cell level equal numbers of both genes are delivered. However, in PET imaging we cannot image single cells; we are concerned with the macroscopic scale of multicell substructure and tissues. Once administered into the living animal, identical vectors carrying the therapeutic and PET reporter genes have an equal statistical chance of infecting each cell. Therefore, a reasonable correlation between infection of both vectors can be expected at the macroscopic level. Our results provide evidence for this hypothesis. Another limitation of delivering therapeutic and reporter genes on separate adenoviruses is the concomitant increase of viral burden and a greater chance of immunological reactions. In the studies presented here we co-administered a control replication-deficient adenovirus to be certain that all animals received the identical viral burden when lower doses of Ad-CMV-D 2 R and Ad-CMV-HSV1-sr39tk were administered. Furthermore, with the use of less immunogenic adenoviral vectors the increased viral burden may not be a problem.
For the purpose of quantifying the expression levels of a therapeutic gene from quantitative PET images of a linked PRG an in vivo fixed linear relationship should be determined. However, it should be noted that both in vitro and in vivo, there is a specific range of PRG and therapeutic gene expression levels at which a reasonable correlation and a fixed linear relationship exists. At high viral titers (0.5-1.5 × 10 9 p.f.u.) we reached saturation of reporter probe activity in the livers of nude mice, as observed by microPET liver images. Furthermore, the level of gene expression is cell type dependent. For example, the higher range of multiplicity of infections (MOI) of the adenoviruses used to infect the C6 cells (0-300 MOI) resulted in lower PRG expression levels than the lower range (0-50 MOI) used to infect COS-1 cells (refer to Figure 2 ). Therefore, when therapeutic genes are co-administered with PRG, in practice, some preliminary studies will be required to determine the appropriate range where a fixed linear relationship exists between the expression of both genes. In the current work we have used %ID/g as a quantitative measure of reporter gene expression. This is a relatively crude measure as it does not take advantage of kinetic information for a given reporter probe to separate out processes such as flow, uptake, trapping, etc. We are currently developing pharmacokinetic models 33 and should be able to improve correlations by more accurate quantitation of reporter gene expression.
A good correlation was also observed at different timepoints of imaging, up to a month between the activity of Figure 6b , those data fit into the fixed linear relationship shown in Figure 4b . Therefore, these data suggest that in practice the correlation between the expression of the therapeutic gene and the PRG may hold up for a substantial time following coadministration of the two viruses. In conclusion, it is possible to track the biodistribution, magnitude and duration of a therapeutic gene delivered in an adenovirus vector by simply co-administering an otherwise identical adenovirus vector expressing a PET reporter gene. 
Materials and methods

Radioactivity determinations
All tritium analysis was performed with a Beckman LS-6500 Liquid Scintillation Counter and Cytoscint (ICN, Costa Mesa, CA, USA) as scintillation fluid. Disintegrations per minute (d.p.m.) were obtained by correcting for background activity and efficiency (67%) based on calibrated standards (Beckman, Inc., Fullerton, CA, USA).
Adenoviral vectors
Dopamine-2 receptor adenovirus (Ad-D 2 R) was constructed by inserting the cloned rat D 2 R coding sequence behind CMV promoter into the E1 region of a replication defective type 5 adenovirus. 16 Construction of HSV1-tk adenovirus (Ad-CMV-HSV1-tk) was performed as described previously.
14 However, for the experiments reported here, the mutant HSV1-sr39tk gene was inserted between the CMV immediate-early promoter and the SV40 splice and poly A site. 36 The control virus, Ad5-dl434, is an E1 deletion mutant with viral sequences between 2.6 and 8.7 map units deleted. 9 p.f.u.) were coinjected into the tail veins of the immunodeficient nude mice. Ad5-dl434 was added to the adenoviral mix, if needed, to bring the total viral titer to a constant level. For in vivo imaging of the PRGs in mouse muscle and implanted tumors, equivalent titers of both viruses were injected directly into the muscles or the tumors. D 2 R binding assay Cells stored free of media at −20°C were harvested by scraping in 6 ml of TE buffer (10 mm Tris-HCl; 1 mm EDTA; pH = 7.5). The cells were then pelleted and resuspended in 200 l TE buffer. Cell lysates were then prepared by sonication. Proteins were then separated from chunks by centrifugation at 400 g. Cell lysates were then diluted at 25 g total protein per 200 l assay solution (5 mm Tris-HCl pH = 7.4; 150 mm NaCl; 0.025% ascorbic acid: 0.001% bovine serum albumin). For in vitro assay of D 2 R expression in the liver, small pieces of liver were homogenized in a buffer consisting of 25 mm Tris (pH = 7.5), 6 mm MgCl 2 , 2 mm EDTA, 0.25 m sucrose, 300 m PMSF and 1 mm benzamidine on the day of extraction. 500 l of the homogenate was then sonicated for 10 s and the homogenate was spun down at 400 g. The supernatants from liver homogenates were diluted at 150 g total protein per 200 l assay solution. Samples were incubated with 3 nm [ TK enzyme assay Cells were harvested by trypsinization and pelleted. The cells were lysed by dissolving the pellet in TK lysis buffer (10 mm Tris-HCl pH = 7.5; 3 mm 2-mercaptoethanol; 0.5% Igepal CA-630; 25 mm NaF) and twice freeze-thawing. Liver pieces were homogenized on the day of extraction in 4 ml of TK lysis buffer. Proteins were separated by centrifuging in a microcentrifuge at 14 000 r.p.m., 4°C, 20 min. Protein concentrations in the supernatant were determined by the BioRad Protein Microassay procedure. Cell (1 g total protein) or liver (2 g total protein) lysates were incubated in a 37°C water bath for 20 F]FDG (anesthetized during the waiting period) before being scanned. Immediately before scanning the mice were anesthetized with ketamine/xylazine and imaged for 28 min using a microPET scanner with a 2 3 mm 3 volumetric resolution. The long axis of the mouse was parallel to the long axis of the scanner and 7-bed positions with 4 min per bed were used. Images were reconstructed by using filtered-back projection and an iterative three-dimensional reconstruction technique with an isotropic image resolution of 1.8 mm and a volumetric resolution of approximately 8 mm 3 .
42
Quantitation of fluorine-18 retention in the livers, muscles and implanted tumors in nude mice Regions of interest (ROI) were drawn over left liver lobe, muscle, or tumor on decay corrected whole body coronal images. The counts/pixel/min obtained from the ROI were converted to counts/ml/min by using a calibration constant obtained from scanning a cylinder phantom in the microPET scanner. The ROI counts/ml/min were converted to counts/g/min, assuming a tissue density of 1 g/ml, and divided by the injected dose to obtain an image ROI derived percent injected dose of radionuclide per gram of tissue.
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